| The Leeds Teaching Hospitals NHS Trust | Title | LTHT / UoL Human Tissue Act (HTA) Someone Operating Procedures applying to the Relatence Reporting HTA related Adverse Events and New Misses | | | | to the Research |
|---|---------------------|--|------------------------|-------------|----------|--|
| UNIVERSITY OF LEEDS Standard Operating Procedure | Scope | under | the LTHT arch Licer | and UoL Hun | nan Tiss | Adverse Events ue Authority ew to include Near |
| | Version | 2.0 | Date issued | April 2020 | SOP ID | LRTB SOP M08 |
| | Planned Review date | | 2022 | | | |

CONTENTS

| Contents | | page 01 |
|-----------|---------------------------------|---------|
| Section A | Standard Operating Procedure | page 02 |
| Section B | SOP detail and approval process | page 07 |
| Section C | Applicability | page 08 |
| Section D | Background | page 08 |
| Section E | Definitions | page 09 |
| Section F | References | page 09 |

LRTB SOP M08 Version 2 April 2020 Page 1 of 9

Section A LTHT / UoL Standard Operating Procedure

1. What is an adverse event?

- 1.1 Adverse events (AEs) are not defined by the Human Tissue Authority for the research licence. A general definition is an event which does not meet the required HTA Standards of Consent, Governance and Quality, Traceability and finally Premises, Facilities and Equipment.
- 1.2 Another important definition is an event that has the potential to cause distress to patients, other donors or their families and in a wider context could result in adverse publicity that may lead to damage in public confidence in the Trust or the University.
- 1.3 Specific examples include absence of documented consent to store donor identifiable samples, specimen loss, incorrect documentation, equipment failure or inappropriate disposal.

2. What is a near miss?

- 2.1 A near miss in the context of the research licence is when an error or failure is corrected in time to prevent an adverse event. It includes deviations from agreed practices.
- 2.2 Examples include:
 - errors in the completion of the consent form that are corrected with the donor before a sample is used:
 - a freezer failure, whether due to interruptions to power supply or a failure of the freezer itself, that is corrected in time to prevent specimen loss.

3. Process for reporting an adverse event

- 3.1 All AEs must be reported in "real time".
- 3.2 Any member of staff who suspects a HTA related AE has occurred should contact the Person Designated (PD) for their area immediately. In the absence of the PD, in the first instance, the individual should contact the academic lead for their research group or their line manager. Local forms of reporting, including deviation reports, can be used alongside this SOP.
- 3.3 The Leeds Teaching Hospitals NHS Trust (LTHT) and the University of Leeds (UoL) incident reporting requirements, as per appropriate policies, should continue as appropriate.
- 3.4 The Person Designated (PD)/Research Lead/Line Manager, must, in the first instance contact the Designated Individual (DI) for the Research Licence or the HTA Manager immediately with details of the incident, location and staff involved, completing the AE reporting form in appendix A.
- 3.5 Any AE must be investigated and a root cause analysis undertaken. Depending on the level of severity and which organisation's (LTHT or UoL) processes are followed, the investigation may be performed independently from HTA-related staff. The results of the investigation

LRTB SOP M08 Version 2 April 2020 Page 2 of 9

- must be made available to the PD, DI and HTA Manager, who will jointly review the Corrective and Preventative Action (CAPA) plan to ensure that it is consistent with compliance with HTA standards.
- 3.6 A named individual will be responsible for the delivery of the CAPA plan. A final report must be submitted to the DI and HTA Manager.
- 3.7 The DI will be responsible for escalating any AEs, particularly those that are systematic, through the accountable officers identified in the joint policy for the storage and use of human tissue.
- 3.8 It is also the responsibility of the DI to determine if an incident warrants rapid referral to the HT Authority for transparency, guidance and/or sharing of good practice.
- 3.9 The DI will include a summary of the AE in their assurance report to the HTA Management Group.

4. Process for reporting near misses

- 4.1 Any member of staff who suspects a HTA related near miss has occurred should contact the Person Designated (PD) for their area immediately. In the absence of the PD, in the first instance, the individual should contact the academic lead for their research group or their line manager. Local forms of reporting, including deviation reports, can be used alongside this SOP.
- 4.2 LTHT / UoL incident reporting requirements, as per appropriate policies, should continue as appropriate.
- 4.3 The causes of the near miss must be investigated and measures put in place to prevent a reoccurrence.
- 4.4 Details regarding near misses should be collectively prospectively based on appendix B.
- 4.5 The PD will be provided with a spreadsheet with all the data items listed in appendix B. This spreadsheet must be submitted to the DI and the HTA Manager every six months and include all near misses in the PD's area of responsibility.

5. Process for sharing and learning

- 5.1 All reports of AEs and near misses will be reviewed at the six monthly HTA Research Subgroup meeting which includes all PDs and associated staff.
- 5.2 This will allow the identification of trends in the occurrence of AEs and near misses including the types of incidents, their location and causes.
- 5.3 If common causes are identified, a CAPA plan will be developed and implemented. A named lead for the development of the plan will be nominated by the HTA research subgroup, and she/he will be supported by named members of staff as appropriate. The timeline for completion will also be agreed.
- 5.4 The DI is responsible for reporting all AEs and near misses and resulting actions within the compliance report that must be submitted to the HT Authority every two years. The compliance report is a requirement for the continuation of the research licence.

LRTB SOP M08 Version 2 April 2020 Page 3 of 9

Appendix A

| <u>Leeds HTA Research Licence</u> <u>Adverse Event (AE) Reporting Form</u> | | | | | |
|---|-------------------------|---|------------------|--|--|
| Name of Person Designat (PD) | ed | | | | |
| Name and contact details of person reporting the event if not the PD | | Name: Contact details: | | | |
| Date of AE | | | | | |
| Date AE discovered | | | | | |
| Date AE reported to the D and HTA manager | I | | | | |
| Reasons for delay in discovery or reporting if applicable | | | | | |
| Name and contact details of the local manager(s) informed | | Name: Contact details: | | | |
| Location where the event took place | | | | | |
| Employment status of the staff involved (select one and complete details) | | LTHT substantive contract - honorary UoL contract yes/no UoL substantive contract - honorary LTHT contract yes/no Other | | | |
| Lead for the internal investigation | | Name: Contact details: | | | |
| Anticipated date of completion of the investigation | | | | | |
| Event details | | | | | |
| Part of process the | LVEIIL UCIAIIS | | | | |
| event was linked to | | Consent | ☐ Transportation | | |
| | | Procurement | Processing | | |
| | | Storage | Distribution | | |
| | Other – please specify: | | | | |
| Description of event | | | | | |
| Suspected cause of the | | | | | |
| event | | | | | |

LRTB SOP M08 Version 2 April 2020 Page 4 of 9

| Action taken to date | | | |
|----------------------|--|--|--|
| | | | |
| | | | |
| | | | |

Reporting adverse events and near misses

LRTB SOP M08

Appendix B

LTHT/UoL HTA Research Licence SOP

Note: This will be provided as a spreadsheet to PDs to complete with all near misses every six months.

| Leade UTA Decemblicance | | | | | | | |
|--|------|-------------------------|------------------|--|--|--|--|
| <u>Leeds HTA Research Licence</u> Near Miss Report Details | | | | | | | |
| iveal iviiss nepult Details | | | | | | | |
| Name of Person Designat (PD) | ed | | | | | | |
| Name and contact details person reporting the even | | Name: | | | | | |
| not the PD | • •• | Contact details: | | | | | |
| Date of near miss | | | | | | | |
| Date near miss discovered | d | | | | | | |
| Reasons for delay in discovery if applicable | | | | | | | |
| Name and contact details | of | Name: | | | | | |
| the local manager(s) informed (if applicable) | | Contact details: | | | | | |
| Location where the near miss took place | | | | | | | |
| Lead for the internal | .\ | Name: | | | | | |
| investigation (if applicable) | | Contact details: | | | | | |
| Near miss details | | | | | | | |
| Part of process the incident was linked to | | Consent | ☐ Transportation | | | | |
| | | Procurement | Processing | | | | |
| | | Storage | ☐ Distribution | | | | |
| | | Other – please specify: | | | | | |
| | | | | | | | |

LRTB SOP M08 Version 2 April 2020 Page 5 of 9

Reporting adverse events and near misses

LRTB SOP M08

LTHT/UoL HTA Research Licence SOP

LRTB SOP M08 Version 2 April 2020 Page 6 of 9

Section B SOP details and approval process Details:

Previous Author: Clare Skinner, as Chair of the Research Subgroup, LTHT/UoL HTA Research Licence

Reviewer: Patricia Harnden, Designated Individual for the Research Licence

SOP Pages: 09

Version No. of replaced SOP: 1.0 (HTA SOP Incident Reporting)

Effective date of replaced SOP:

Review date for updated SOP:Biennially from date of approval or review

Review Date: By:

Review and Approval Process:

| Draft | Circulated to | Period of circulation (dates) | Comments received from |
|-------------|--|--|--|
| Version 0.1 | All Persons Designated and key associated staff, HTA Manager, LTHT and UoL Research and Innovation, Medical Achiever leaders | January x to February 29 2020 Discussed at the HTA Research Subgroup meeting on 13/02/2020 | No written comments were received Agreement at the meeting to drop "serious" and refer only to adverse events. |

| | on No e SOP | Name of DI | Date | Signature |
|---|----------------|---|------------|-----------|
| 2 | 2.0 | Dr Patricia Harnden Designated Individual LTHT/UoL Human Tissue Act | 07/04/2020 | 78-1 |
| | | | | |

Distribution & Storage:

Distribution to

Persons Designated, LTHT/UoL HTA Research Licence, HTA Research Subgroup

Location of Document

Paper: HTA Manager, Risk Management, The Trust Headquarters, St James's University Hospital

Electronic: Research and Innovation website, UoL., http://ris.leeds.ac.uk/info/72/relevant_legislation/107/hta/2

LRTB SOP M08 Version 2 April 2020 Page 7 of 9

Section C Applicability

- 1.1 This SOP is relevant to all staff collecting and storing human tissues relevant to the Act. The list of relevant tissues can be found on the Human Tissue Authority website by following the link:
 - http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/definitionofrelevantmaterial.cfm
- 1.2 This SOP can also be used as a training tool for new members of staff who have never worked with human tissues before, or who need to follow a new process.
- 1.3 This SOP does not replace incident reporting requirements within LTHT or UoL as appropriate, which should continue as is current practice.

Section D Background

- 1.1 Different sample types (blood or other bodily fluids, surgical resections etc) and data are collected from patients and other donors in Leeds for future unspecified research into a wide range of conditions including the investigation of normal cellular functions and their disruption in disease states, whether cancer or non-cancer. The tissue collections resulting from these different research activities are grouped under one research licence granted by the Human Tissue Authority to cover both Leeds Teaching Hospitals NHS Trust and the University of Leeds and referred to as the Leeds Research Tissue Banks. However, not all of these tissues are held within an NHS Research Ethical Committee approved research tissue bank.
- 1.2 The Leeds Teaching Hospitals NHS Trust is registered as the Licence Holder with the HT Authority, and the principal licensed site ('the hub') is St James's University Hospital Trust. The University of Leeds main campus and Chapel Allerton Hospital are named satellites on the licence.
- 1.3 The Licence Holder is responsible for appointing a suitable Designated Individual (DI).
- 1.4 The DI plays a key role in implementing the requirements of the HT Act as the person under whose supervision the licensed activity is authorised to be carried out. The DI has the primary (legal) responsibility under Section 18 of the HT Act to secure that:
- 1.4.1 suitable practices are used in undertaking the licensed activity;
- 1.4.2 other persons, such as the Persons Designated (PDs), working under the license are suitable and:
- 1.4.3 the conditions of the licence are complied with.
- 1.2 This SOP has been written to formally establish a consistent procedure for the reporting of HTA related Near Misses and Adverse Events. In line with the relevant codes of practice for research establishments licensed by the HTA, this SOP lays out the internal system for reporting adverse events and, where necessary, instigating an investigation or root cause analysis. In a research environment, the focus may be on non-compliance with the HT Act and codes of practice or damage to the tissue integrity; for example, through inappropriate storage.

LRTB SOP M08 Version 2 April 2020 Page 8 of 9

1.3 The main aim of this SOP is to ensure that relevant staff, by referencing this document, can easily follow the process of reporting of HTA related Near Misses and Adverse Events.

Section E Definitions

The Act The Human Tissue Act, 2004

DI Designated Individual as defined by the Human Tissue Authority

HT The Human Tissue Authority or Act

LTHT Leeds Teaching Hospitals NHS Trust

PD Person Designated as defined by the Human Tissue Authority

R&I Research & Innovation

SOP Standard Operating Procedure

UoL University of Leeds

Section F References

Human Tissue Act, 2004

Human tissue Authority, Codes of Practice 2017

Code A: Guiding principles and the fundamental principle of consent

Code E: Research

Code E: Research standards and guidance

Joint Policy for the Storage and Use of Human Tissue – a collaborative document agreed by Leeds Teaching Hospitals NHS Trust

LRTB SOP M08 Version 2 April 2020 Page 9 of 9